

Integration of Neoadjuvant Chemotherapy and Interval Debulking Surgeries in Patients with Advanced Epithelial Ovarian Cancer

Loaie El-Helw^{1,2}, Abeda Raiyan¹, Rajanee Bhana¹

¹ The Cancer Centre, the Royal Stoke University Hospital, Stoke-on-Trent, UK

² The Department of Internal Medicine, the Medical Oncology Unit,

Mansoura University, Mansoura, Egypt

loaieelhelw@hotmail.com, loaie.elhelw@uhns.nhs.uk

Abstract: Neoadjuvant chemotherapy (NAC) and interval debulking surgery (IDS) after 3 NAC cycles is an acceptable approach to achieve optimal cytoreduction in patients with advanced epithelial ovarian cancer (AEOC) who are not candidate for primary debulking surgery (PDS). The best timing of cytoreductive surgery and the role of late debulking surgery (LDS) after 6 cycles of NAC are still unclear. We aimed to study the outcome of such patients who were treated in our centre in the Royal Stoke University Hospital, Stoke-On-Trent between July 2009 and July 2014. One hundred and eight patients with AEOC were treated under our gynaecology oncology team during that period. Sixty six patients (61.1%) were in stages III and 42 (38.9%) in stage IV. All patients received NAC; 64 patients (59.3%) had paclitaxel and carboplatin regimen and 44 (40.7%) single agent carboplatin. Response to chemotherapy was assessed after 2 cycles; 81 patients (75%) had partial response, 21 (19.4%) stable disease and 6 (5.6%) progressive disease. Forty one patients (38%) proceeded to IDS after cycle 3 and 11 patients (10.2%) to LDS after cycle 6 but 56 (51.9%) had no debulking surgery (NDS). After a median follow up period of 18 months (range 6-84 months), 95 patients (88%) had relapsing/progressive disease. The median PFS durations were 13 and 12 months for patients who had either IDS and LDS respectively compared to 8 months for NDS. The 2 years PFS probabilities were 18% for patients who had IDS, 15% for LDS compared to 0% for NDS (P 0.000 Log rank test). The median overall survival (OS) durations were 48, 33 and 18 months for patients who had IDS, LDS and NDS respectively. The 2 years OS probabilities were 75% for patients who had either IDS, or LDS compared to 38% for NDS (P.000 Log rank test). In our study, we documented PFS and OS advantages for patients who IDS or LDS compared to NDS and therefore should be considered whenever possible as part of the primary treatment of AEOC patients. Interval debulking surgery (IDS) offers longer duration and higher probabilities of PFS and OS compared to LDS. More patients-therefore- should be selected for IDS. There is a need for improving NAC possibly with integrating target agents and the use of more intensified schedules.

[Loaie El-Helw, Abeda Raiyan, Rajanee Bhana. **Integration of Neoadjuvant Chemotherapy and Interval Debulking Surgeries in Patients with Advanced Epithelial Ovarian Cancer.** *Cancer Biology* 2016;6(4):9-15]. ISSN: 2150-1041 (print); ISSN: 2150-105X (online). <http://www.cancerbio.net>. 2. doi:[10.7537/marscbj060416.02](https://doi.org/10.7537/marscbj060416.02).

Key words: advanced ovarian cancer-neoadjuvant chemotherapy-surgical debulking

1. Introduction

Approximately 70% to 80% of the ovarian cancer patients are in stage III or IV when first diagnosed. The current standard treatment for epithelial ovarian cancer (EOC) consists of primary debulking surgery (PDS) followed by paclitaxel and platinum chemotherapy. Optimal cytoreduction-in those patients-to no macroscopic residual disease is difficult to achieve with reported rate of less than 25% despite maximal efforts [1]. Also, most patients diagnosed with advanced epithelial ovarian cancer (AEOC) are elderly, with multiple comorbidities, and poor performance status. Therefore aggressive surgery is significantly limited in these patients.

Neoadjuvant chemotherapy (NAC) is associated with 70-80% response rate in AEOC and can result in adequate tumour shrinkage. Therefore, NAC followed by interval debulking surgery (IDS) has been considered as an alternative to conventional PDS in

treating AEOC [2, 3]. The timing of IDS is usually after 2-4 cycles of chemotherapy. The value of late debulking surgery (LDS) after 6 cycles is not clear as there is a chance of emergence of more chemotherapy resistant tumour clones. Therefore, in our study we reviewed the management of our patients who presented with AEOC and were not candidate for PDS. We studied their outcome in relation to timing of debulking surgeries.

2. Patients and Methods

This was a retrospective study of patients with advanced ovarian cancer who had been treated with NAC with or without IDS/LDS in the cancer centre, the Royal Stoke University Hospital, UK since July 2009 till July 2014. Electronic patients and gynaecology multidisciplinary team (GMDT) meetings records were reviewed. Data analysis was performed using SPSS statistical package version 16.

Overall survival (OS) and progression-free survival (PFS) probabilities were analysed using the Kaplan-Meier method. The log-rank test and Cox-regression multivariate analysis were used to investigate the differences in survival between the study groups. $P < 0.05$ was considered statistically significant.

3. Results

Table 1 describes the demographic features of the patients in the study. One hundred and eight

patients with AEOC who were not candidate for PDS were included. The median age was 71 years old (range 37-86). Sixty six patients (61.1%) presented in clinical stage (CS) III and 42 (38.9%) CS IV. Serous papillary adenocarcinoma was the most common histologic subtype (92.6%). Eight patients (7.4%) presented with primary peritoneal carcinomatosis (PPC) but the majority (92.6%) had advanced ovarian cancer presenting with adnexal masses and wide spread diseases.

Table (1) Demographic Data of the 108 Studied Patients

Variables		Number of Patients 108	Percent 100
Clinical stage	III	66	61.1
	IV	42	38.9
Grade	Grade 3	105	97.2
	Missing data	3	2.8
Histology	Serous	100	92.6
	Clear cells	3	2.8
	Carcinosarcoma	2	1.9
	Endometrioid	1	0.9
	mucinous	1	0.9
	Undetermined subtypes	1	0.9
Clinical subtypes	EOC	100	92.6
	PPC	8	7.4
GMDT plan	NAC/IDS	104	96.3
	Palliative Chemotherapy	4	3.7
NAC	Paclitaxel and carboplatin	64	59.3
	Carboplatin	44	40.7

EOC: epithelial ovarian cancer, **PPC:** primary peritoneal carcinoma, **NAC:** neoadjuvant chemotherapy, **IDS:** interval debulking surgery. **GMDT:** gynaecology multidisciplinary team.

All our patients were discussed in the GMDT meetings on initial presentations where their management plans were decided. One hundred and four (96%) patients were considered for NAC/IDS and 4 patients (3.7%) were to have palliative chemotherapy only due to poor performance status (PS). All patients were reviewed once again after 2 cycles of chemotherapy for possibility of IDS. Paclitaxel and carboplatin regimen was the most commonly used NAC (59.3%) and single agent carboplatin was used in the rest of patients (40.7%).

Response to chemotherapy was assessed after 2 cycles of chemotherapy and patients were re-discussed in the GMDT meetings. Eighty one patients (75%) had partial response (PR) to chemotherapy, 21 (19.4%) stable disease (SD) and 6 (5.6%) progressive disease (PD) (table 2). Forty one patients (38%) proceeded to have IDS after 3 cycles and 11 (10.2%) had LDS. Overall 52 patients (48.2%) had IDS/LDS. More patients with CS III proceeded to have debulking surgeries than CS IV (59.1% versus 30.9%). Complete

surgical cytoreduction was achieved in 46 patients (88.5%) but 6 patients (11.5%) had suboptimal debulking with residual macroscopic disease. Maximal cytoreduction was achieved in all of the 11 patients (100%) who had LDS and in 35 patients of the 41 who had IDS (85.4%) (table 2).

After a median follow up period of 12 months (range 6-40), 95 patients (88%) had relapsing/progressive disease and had a median of 2 (range 1-4) further lines of systemic anticancer treatment (SACT). Thirty seven out of 41 patients (90.2%) who had IDS and 6 out 11 patients (54.5%) who had LDS have eventually relapsed. Most patients (92.9%) who did not have any debulking surgery had PD. Only 4 patients (4.2%) had single area of relapse and one of them underwent further surgical resection followed by chemotherapy. Forty out of 43 patients (93%) with IDS/LDS had platinum free interval (PFI) of ≥ 6 months compared to only 63.5% for patients with no debulking surgery ($P 0.001$ Fischer Exact test) (Table 3).

Table (2) Response and Outcome

Variables		Number	Percent	
Response after 2 cycles (108 patients)	PR	81	75	
	SD	21	19.4	
	PD	6	5.6	
Number of cycles to debulking (108 patients)	3 Cycles (IDS)	41	38	
	6 cycles (LDS)	11	10.2	
	No debulking	56	51.8	
*Debulking in relation to stage CS III (66 patients)	IDS (after 3 cycles NAC)	32	48.5	
	LDS (after 6 cycles NAC)	7	10.6	
	No debulking	27	40.9	
CS IV (42 patients)	IDS (after 3 cycles NAC)	9	21.4	
	LDS (after 6 cycles NAC)	4	9.5	
	No debulking	29	69	
Surgical Cyto-reduction (52 patients)	Complete	46	88.5	
	Incomplete (residual disease)	6	11.5	
**Degree of cyto-reduction in relation of timing of debulking	IDS (41 patients)	Complete	35	85.4
		Incomplete	6	14.6
	LDS (11 patients)	Complete	11	100
		Incomplete	0	0

NAC: neoadjuvant chemotherapy, **IDS:** interval debulking surgery (after 3 cycles), **PR:** partial response, **SD:** stable disease, **PD:** progressive disease. **LDS:** late debulking surgery (after 6 cycles). * P value= 0.003 (Chi-square), ** P value= 0.000 (Chi-square). CS: clinical stage

Table (3) Relapse Data among the Studied Patients

Variables		Number	Percent	
Relapse/progression (108 patients)	Yes	95	88	
	No	13	12	
*Relapse in relation to IDS/LDS	IDS (41 patients)	Yes	37	90.2
		No	4	9.8
LDS (11 patients)	Yes	6	54.5	
	No	5	45.5	
No debulking (56 patients)	Yes	52	92.9	
	No	4	7.1	
Relapse in relation to degree of cyto-reduction	Complete (46 patients)	Yes	38	82.6
		No	8	17.4
	Incomplete (6)	Yes	5	83.3
		No	1	16.7
Pattern of relapse (95 patients)	Isolated site	4	4.2	
	Multiple areas	91	95.6	
PFI (108 patients)	Refractory	4	3.7	
	< 6 months	18	16.7	
	6-12 months	50	46.3	
	>12 months	36	33.3	
** PFI In Relation to debulking surgeries	IDS/LDS (43 relapsed patients)	<6 months/refractory	3	7
		6-12 months	18	41.8
		>12 months	22	51.2
	No debulking (52 relapsed patients)	<6 months/refractory	19	36.5
		6-12 months	25	48.1
>12 months		8	15.4	

IDS: interval debulking surgery, **LDS:** late debulking surgery, **SACT:** systemic anticancer treatment. **PFI: Platinum free interval** * P.005 (Fisher Exact test), ** P.001 (Fisher Exact test).

The median progression free survival duration (PFS) for all patients was 11 months (range 10-12 months) and 2 years PFS probability was 10% (Figure 1). The median PFS was 13 months (range 9-16) for patients who had IDS and 12 months (range 10-13) for patients who had LDS compared to 8 months (range 6-9) for NDS (P 0.000 by Log RankTest) (figure 2).

Figure (1) Progression Free Survival for All Patients





Figure (2) Progression Free Survival In Relation to Timing of Debulking Surgeries



The median PFS durations were 13, 10 and 8 months for patients who had complete, incomplete cytoreduction or no debulking respectively (P 0.000 Log Rank Test) although the difference in median PFS for complete and incomplete cytoreduction was statistically insignificant (p 0.201). None was statistically significant in Cox-regression analysis.

The median overall survival duration for all patients was 27 months (range 5-54 months) and (the 2 years OS probability was 52% (figure 3). The median OS durations in relation to timing of debulking surgery is shown in Figure 4. They were 48, 33 and 18 months for IDS, LDS and NDS respectively (P 0.442 Log Rank Test). Figure 4.

Figure (3) Overall Survival for All Patients





Figure (4) Overall Survival In Relation to Timing of Debulking Surgeries

The 2-years survival probability was 75% for patients who had either IDS or LDS compared to 38% for no debulking. All patients with suboptimal debulking are still surviving at a median of 11 months follow up (range 9-12 months).

Patients who had platinum free interval (PFI) of > 12 months have the highest survival probability compared to PFI of 6-12 months, < 6 months and refractory patients. Median durations of OS were (38, 24, 21 and 12 months respectively) (P. 022). In Cox-regression multivariate analysis, none of these variables was statistically significant.

4. Discussion

Neoadjuvant chemotherapy and interval debulking surgery (NAC/IDS) is an acceptable approach to achieve optimal cytoreduction in patients with advanced epithelial ovarian cancer who are not candidate for primary debulking surgery [4-6]. The best timing to perform cytoreductive surgery after NAC is still unclear. In a meta-analysis by Bristow and Chi, it was found that increasing the number of chemotherapy cycles prior to the debulking surgery had a negative survival effect. Thus, a definitive operative intervention should be undertaken early in the treatment program as possible [7].

That concept was also reported by Colombo and colleagues who found that patients with AEOC receiving complete IDS after more than 4 cycles of NAC have poor prognosis [8]. However, another meta-analysis did not show that increasing the number of NAC cycles adversely affected OS [3].

In our study, 108 patients with stage III and IV AEOC were not candidate for primary debulking surgery (PDS) and therefore were offered NAC and consideration of IDS. All patients were re-discussed in

our GMDT meetings following 2 cycles of NAC with radiological and biochemical assessment for evaluation of responses and eligibility for IDS. Accordingly 41 patients (38%) had adequate response and proceeded to IDS after 3 NAC cycles. Fifty six patients (51.9%) were not candidate -for debulking surgeries for wide spread disease distribution and/or inadequate response to NAC. The rest of our patients (11 patients; 10.2%) showed slow response to NAC based on radiological or laparoscopic assessment and therefore complete cytoreduction was considered non-achievable at that stage. They have been further reassessed following cycle 5 of NAC and proceeded to LDS. Overall, higher PFS was achieved for patients who had IDS or LDS compared to no debulking (13, 12 and 8 months respectively).

The median survival durations were 48, 33, 18 months for IDS, LDS or NDS respectively. The 2 years OS probabilities were 75% for IDS or LDS patients compared to 38% for patients who had NDS. These findings emphasize the importance of debulking surgeries whether IDS or LDS as they are associated with better PFS and OS compared with no debulking.

The definition of 'optimal cytoreduction' has moved from its former meaning of a cytoreduction to ≤ 1 cm of residual disease to no residual disease [9, 10]. Tumour resection with > 1 cm of residual disease (15-30% of patients) places these patients at risk of morbidities of the cytoreductive attempt without survival benefit [11]. In agreement with that, our patients who had optimal debulking surgeries, had significantly longer median PFS compared to patients who had suboptimal debulking surgeries or no debulking at all (13, 10 and 8 months respectively). Patients, who had IDS/LDS, had higher chance of having platinum sensitive disease (93%) compared to

NDS patients (63.5%) on relapse. As expected the median OS was higher for patients with platinum sensitive relapse compared to platinum resistant or platinum refractory patients (median OS durations of 38, 24, 21 and 12 months respectively).

On conclusion, IDS and LDS offer better PFS and OS for patients with AEOC than NDS. Interval debulking surgery (IDS) offers longer duration and higher probabilities of PFS and OS compared to LDS. Debulking surgeries in patients with AEOC increase the percentage of patients who have platinum free interval of ≥ 6 months and therefore have more chances to respond to further platinum regimens. More patients-therefore- should be selected for IDS/LDS. There is a need for improving NAC possibly with integrating target agents and the use of more intensified schedules. The ongoing ICON8B trial [12] is currently addressing that in a randomised (1:1:1 ratio), three-arm, phase III study designed to evaluate the safety and efficacy of bevacizumab in combination with dose-dense, dose-fractionated carboplatin-paclitaxel chemotherapy compared to either strategy alone for the first-line treatment of ovarian cancer.

Corresponding Author:

Dr Loai M El-Helw

The cancer centre, the Royal Stoke University Hospital, Stoke-On-Trent, ST4 6QG, UK.

loaiehelw@hotmail.com, loaie.elhelw@uhns.nhs.uk

Egyptian University Affiliation:

The Internal Medicine department, the Medical Oncology Unit, Mansoura University, Mansoura, Egypt.

References

1. Gallo A., and Frigerio L.: Neoadjuvant chemotherapy and surgical considerations in ovarian cancer. *Curr. Opin. Obstet. Gynecol.*, 15(1): 25-31, 2003.
2. Morice P., Dubernard G., Rey A., et al.: Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. *J. Am. Coll. Surg.*, 197 (6):955-63, 2003.
3. Kang S., and Nam BH.: Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. *Ann. Surg. Oncol.*, 16 (8): 2315-20, 2009.
4. Zheng H., and Gao Y.: Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. *Chin. J. Cancer Res.*, 24(4): 304-309, 2012.
5. Keyver-P., Zivanovic O., and Rudlowski C.: Interval debulking surgery in patients with Federation of Gynecology and Obstetrics (FIGO) stage IIIC and IV ovarian cancer. *Onkologie.*, 36(6):324-32, 2013.
6. Markauskas A., Mogensen O., dePont Christensen R. et al.: primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter. *Int. J. Gynecol. Cancer.*, 24 (8): 1420-8, 2014.
7. Bristow RE. and Chi DS.: Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. *Gynecol. Oncol.*, 103 (3):1070-6, 2006.
8. Colombo PE., Labaki M., Fabbro M., et al.: Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer *Gynecol. Oncol.* S0090-8258(14)01305-5, 2014.
9. Thigpen T., duBois A., McAlpine J., et al.: First-line therapy in ovarian cancer trials. *Int. J. Gynecol. Cancer*, 21(4):756-62, 2011.
10. Vergote I., Tropé C. and Amant F.: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N. Engl. J. Med.*, 363(10): 943-53, 2010.
11. Chang S. and Bristow R.: Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. *Gynecol. Oncol.*, 125(2):483-92, 2012.
12. ICON8 Overview and Protocol: www.ICON8trial.org/about_ICON8B/Overview_protocol

10/25/2016